miR-647 inhibits hepatocellular carcinoma cell progression by targeting protein tyrosine phosphatase receptor type F

References

• Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellularcarcinoma, Seminars in diagnostic pathology. Elsevier. 2017; 341:153–159.
   Google Scholar
• Xiang K, Yan W, Cheng Z, et al. Prognostic value of SH3PXD2B (Tks4) in human hepatocellular carcinoma: a combined multi-omics and experimental study. BMC Med Genomics. 2021;14(1):115.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477–491.
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. T.M.J.S.o. Pawlik, Hepatocellular carcinoma: from diagnosis to treatment. 2016;25(2):74–85.
   Google Scholar
• Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. Ca A Cancer J Clinicians. 2011;62:60–69.
   Google Scholar
• Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta (BBA)- Rev Cancer. 2020; 1873(1) :188314.
   PubMed Web of Science ®Google Scholar
• Chen Z, Xie H, Hu M, et al. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.
   PubMed Web of Science ®Google Scholar
• Tomita H, Cornejo F, Aranda-Pino B, et al. The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis - ScienceDirect. 2020; 30(1): 215–228.e5 .
   Google Scholar
• Bera R, Chiou CY, Yu MC, et al. Functional genomics identified a novel protein tyrosine phosphatase receptor type f‐mediated growth inhibition in hepatocarcinogenesis. Hepatology. 2014;59(6):2238–2250.
   PubMed Web of Science ®Google Scholar
• Liu G, Shi A, Wang N, et al. Polyphenolic Proanthocyanidin-B2 Suppresses Proliferation of Liver Cancer Cells and Hepatocellular Carcinogenesis through Directly Binding and Inhibiting AKT Activity. Redox Biol. 2020; 37:101701.
   PubMed Web of Science ®Google Scholar
• Tian X, Yang C, Yang L, et al. PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma. Onco Targets Ther. 2018;11:7795–7803.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu H, Su L, et al. PPARγ inhibits breast cancer progression by upregulating PTPRF expression. Eur Rev Med Pharmacol Sci. 2019;23(22):9965–9977.
   PubMed Web of Science ®Google Scholar
• Wu M, Wang G, Tian W, et al. MiRNA-based therapeutics for lung cancer. Curr Pharm Des. 2017;23(39):5989–5996.
   Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Karahan H, Dabin LC, Tate MD, et al. MicroRNAs on the move: microRNAs in astrocyte-derived ApoE particles regulate neuronal function. Neuron. 2021;109(6):907–909.
   PubMed Web of Science ®Google Scholar
• Ruiguang Z, Chunxia G, Ting L, et al. MicroRNA miR-495 regulates the development of Hepatocellular Carcinoma by targeting C1q/tumor necrosis factor-related protein-3 (CTRP3). Bioengineered. 2021;12:6902–6912.
   PubMed Web of Science ®Google Scholar
• Xiaobin C, Jiang Y, Yongbiao C, et al. Upregulation of microRNA miR-652-3p is a prognostic risk factor for hepatocellular carcinoma and regulates cell proliferation, migration, and invasion. Bioengineered. 2021;12:7519–7528.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen T, Cai YJ, et al. MicroRNA-647 promotes the therapeutic effectiveness of argon–helium cryoablation and inhibits cell proliferation through targeting TRAF2 via the NF-κB signaling pathway in non-small cell lung cancer. Onco Targets Ther. 2018;11:6777.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang M, Wang G, et al. Tumor promoter role of miR-647 in gastric cancer via repression of TP73. Mol Med Rep. 2018;18(4):3744–3750.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ouyang X, Xin J, et al. Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients. Int J Med Sci. 2015;12(7):590–598.
   PubMed Web of Science ®Google Scholar
• Xinbei J, Jiali T, Yixuan W, et al. 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. J Med Chem. 2020;63:5972–5989.
   PubMed Web of Science ®Google Scholar
• Hongfei C, Bin G, Xiang Z, et al. Circular RNA hsa_circ_0007364 increases cervical cancer progression through activating methionine adenosyltransferase II alpha (MAT2A) expression by restraining microRNA-101-5p. Bioengineered. 2020;11:1269–1279.
   PubMed Web of Science ®Google Scholar
• Tong L, Tang C, Cai C, et al. Upregulation of the microRNA rno-miR-146b-5p may be involved in the development of intestinal injury through inhibition of Kruppel-like factor 4 in intestinal sepsis.[J].Bioengineered. 2020;11(1):1334–1349.
   Google Scholar
• Qiang G, Xi-Xian K, Shi-Xu F, et al. PAQR3 Inhibits Non-small Cell Lung Cancer Growth by Regulating the NF-κB/p53/Bax Axis. Front Cell Dev Biol. 2020;8:581919.
   PubMed Web of Science ®Google Scholar
• Chedid MF, Kruel CR, Pinto MA, et al. Hepatocellular carcinoma: diagnosis and operative management. Arquivos Brasileiros De Cirurgia Digestiva Abcd. 2017;30. 272–278.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Alsharif U, El Bcheraoui C, et al. Burden of cancer in the Eastern Mediterranean Region, 2005-2015: findings from the Global Burden of Disease 2015 Study. Int J Public Health. 2018; 63(Suppl 1): 151–164 .
   PubMed Web of Science ®Google Scholar
• Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1–10.
   PubMedGoogle Scholar
• Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12–23.
   PubMed Web of Science ®Google Scholar
• Schooneveld E, Wildiers H, Vergote I, et al. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015;17(1):1–15.
   PubMed Web of Science ®Google Scholar
• Hannafon BN, Cai A, Calloway CL, et al. miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study. BMC Cancer. 2019;19(1):1–12.
   PubMed Web of Science ®Google Scholar
• Tsukerman P, Yamin R, Seidel E, et al. MiR-520d-5p directly targets TWIST1 and downregulates the metastamiR miR-10b. Oncotarget. 2014;5(23):12141.
   PubMedGoogle Scholar
• Jiang W, Zhao X, Yang W. MiR-647 promotes cisplatin-induced cell apoptosis via downregulating IGF2 in non-small cell lung cancer. Minerva Med. 2021;112(2):312–313.
   PubMed Web of Science ®Google Scholar
• Qin K, Tian G, Chen G, et al. K Tang. miR-647 inhibits glioma cell proliferation, colony formation and invasion by regulating HOXA9. J Gene Med. 2020;22(3):e3153.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack F. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222.
   PubMed Web of Science ®Google Scholar
• Liu S, Qu D, Li W, et al. miR-647 and miR-1914 promote cancer progression equivalently by downregulating nuclear factor IX in colorectal cancer. Mol Med Rep. 2017;16(6):8189–8199.
   PubMed Web of Science ®Google Scholar
• Cao W, Wei W, Zhan Z, et al. Role of miR-647 in human gastric cancer suppression. Oncol Rep. 2017;37(3):1401–1411.
   PubMed Web of Science ®Google Scholar
• Ye G, Huang K, Yu J, et al. MicroRNA-647 targets SRF-MYH9 axis to suppress invasion and metastasis of gastric cancer. Theranostics. 2017;7(13):3338.
   PubMed Web of Science ®Google Scholar
• Du WW, Fang L, Li M, et al. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci. 2013;126(6):1440–1453.
   PubMed Web of Science ®Google Scholar
• Gan T, Stevens AT, Xiong X, et al. Evers, Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer. Oncogene. 2020;39(44):6789–6801.
   PubMed Web of Science ®Google Scholar
• Karin MJJOBC. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995;270(28):16483–16486.
   PubMed Web of Science ®Google Scholar
• Dae KS, Sue BJ, Jae-Hye L, et al. The malignancy of liver cancer cells is increased by IL-4/ERK/AKT signaling axis activity triggered by irradiated endothelial cells. J Radiat Res. 2020;3:3.
   Google Scholar
• Yamada K, Oikawa T, Kizawa R, et al. Unconventional Secretion of PKCδ Exerts Tumorigenic Function via Stimulation of ERK1/2 Signaling in Liver Cancer. Cancer Res. 2020;81(2):414–425.
   PubMed Web of Science ®Google Scholar